Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depressive Disorder, Major, Borderline P...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Left Dorsolateral Prefrontal Cortex (L-DLPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Dorsomedial Prefrontal Cortex (DMPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Sham Stimulation — Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC. Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.

Primary Outcomes

  • Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active L-DLPFC vs. sham aiTBS. (At baseline (pre-intervention), during the intervention and immediately after the intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-20
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • David Spiegel, MD (STUDY_DIRECTOR) - Stanford University
Contact Information
Study Contact:
Bora Kim, MD, MAS
650-800-6929
borakim2@stanford.edu
Nick Bassano, MSW
650-800-6929
nbassano@stanford.edu
Nick Bassano, MSW1
6504347844
nbassano@stanford.edu
Stanford Hospital
Interventions
  • Device: Left Dorsolateral Prefrontal Cortex (L-DLPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Dorsomedial Prefrontal Cortex (DMPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Sham Stimulation — Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC. Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.
Study Locations (1 sites)
Stanford Hospital, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Male or Female, between the ages of 18 and 80 at the time of screening. * Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. * Diagnosed with Major Depressive Disorder (MDD) or Bipolar II, or unspecified depressive disorder AND Borderline Personality Disorder or trait, with a current Mood Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5). * MADRS score of ≥20 at screening (Visit 1). * TMS naive. * Access to ongoing psychiatric care before and after completion of the study. * Access to clinical rTMS after study completion. * In good general health, as evidenced by medical history. * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation. * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration. Exclusion Criteria: * Pregnancy * The presence or diagnosis of prominent anxiety disorder, personality disorder, or dysthymia * Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation) * Current mania or psychosis * Bipolar I Disorder and primary psychotic disorders. * Autism Spectrum disorder or Intellectual Disability * A diagnosis of obsessive-compulsive disorder (OCD) * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal. * Urine screening test positive for illicit substances. * Any history of ECT (greater than 8 sessions) without meeting responder criteria * Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT). * History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma. * Untreated or insufficiently treated endocrine disorder. * Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) * Contraindications to MRI (ferromagnetic metal in their body). * Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. * Depth-adjusted aiTBS treatment dose \> 65% maximum stimulator output (MSO) * Treatment with another investigational drug or other intervention within the study period. * Any other condition deemed by the PI to interfere with the study or increase risk to the participant.
Conditions HER2-negative Early Breast Cancer
Phase PHASE1, PHASE2
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival. The neoadjuvant treatment for her2 negative patient was chemotherapy with combined drugs. However, not all patients benefit from chemotherapy but suffer from chemotherapy-related side effects. It was unknown for a patient who could benefit from which drug before chemotherapy. Drug sensitivity screening in vitro was a promising method for choosing chemotherapy. But there was no method could select effective drugs accurately for breast cancer patients until now. Previously, investigators developed a patient-derived tumor-like cell clusters in vitro culture technology. Feasibility for guiding clinical treatment by drug sensitivity screening based on this technology have been explored by preliminary exploration with a well corresponding. And the results have been published. This study will explore whether drug screening in vitro patient-derived tumor-like cell clusters from breast cancer tissue could be a method for selection of chemotherapy for her2 negative participants.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer — The choice of chemotherapy is based on the PTC drug sensitivity results.
  • Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer — The choice of chemotherapy is based on the PTC drug sensitivity results.

Primary Outcomes

  • pathological complete response(pCR) (up to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-04-02
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Principal Investigators:
  • Shu Wang, doctor (PRINCIPAL_INVESTIGATOR) - Peking University People's Hospital
Contact Information
Study Contact:
Chaobin Wang, doctor
+86-10-8832-4010
hzwcb1990@163.com
Chaobin Wang, doctor
+86-10-88324010
hzwcb1990@163.com
Peking University People's Hospital
Interventions
  • Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer — The choice of chemotherapy is based on the PTC drug sensitivity results.
  • Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer — The choice of chemotherapy is based on the PTC drug sensitivity results.
Study Locations (1 sites)
Peking University People's Hospital, Beijing, China
Eligibility Criteria
Inclusion Criteria: * invasive breast cancer * HER2 negative * T2 or node positive * Eastern Cooperative Oncology Group(ECOG) 0-1 Exclusion Criteria: * stage IV * inflammatory breast cancer * Severe chronic disease
Conditions Advanced Solid Tumor, Metastatic Breast ...
Phase PHASE1
Enrollment 112
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study will be done in three phases, described below. Phase 1a (Dose Escalation Phase): The Phase 1a portion is designed to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of orally administered BTX-A51. BTX-A51 will be administered once daily on a weekly schedule of 5 days on/2 days off. Dose escalation will proceed according to a modified 3+3 design. Each cycle will consist of 28 days (4 weeks), and the DLT observation period will be the first cycle (i.e., 28 days after initiation of dosing). A DLT may be observed in no more than 0 out of 3 or 1 out of 6 subjects who have completed the DLT observation period before the next cohort initiates accrual. Barring DLT, sequential dose escalation of BTX-A51 is planned with up to a total of 6 dose levels; on the basis of these an MTD will be identified. The MTD is defined as the highest dose level with a subject incidence of DLTs of 0 or 1 out of 6 during the first 28 days of study drug dosing. A minimum of 6 subjects needs to be treated at a dose level before this dose level can be deemed as the MTD. Phase 1b (Monotherapy Dose Ranging Phase): Dose expansion may begin when the RP2D has been determined. Up to 40 additional subjects at each of the 2 dose levels will be enrolled to evaluate safety and preliminary efficacy of BTX-A51 in subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), GATA3 mutant (mt) and wild-type (wt) metastatic breast cancer (mBC). Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days). Phase 1c (Combination Safety Phase): The Phase 1c portion will evaluate the safety and tolerability of orally administered BTX-A51 at two dose levels combined with fulvestrant. The first combo cohort may be initiated after DEC review of the 6 subject lead-in phase of the high dose monotherapy cohort in Phase 1b. Dose escalation will proceed according to a 3+3 design. Each cycle will consist of 28 days (4 weeks), and the DLT observation period will be the first cycle (i.e., 28 days after initiation of dosing).

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BTX-A51 — One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Primary Outcomes

  • Incidence of adverse events after BTX-A51 administration alone and in combination with fulvestrant (From first dose of BTX-A51 through 30 days after the last BTX-A51 alone and in combination with fulvestrant treatment (subjects will be offered continued access to study BTX-A51 until disease progression or unacceptable toxicity))
  • Defining the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of BTX-A51alone and in combination with fulvestrant (At the end of Cycle 1 (each cycle is 28 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-06-07
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Edgewood Oncology Inc.
Principal Investigators:
  • Zung Thai, MD (STUDY_DIRECTOR) - Edgewood Oncology Inc.
Contact Information
Study Contact:
Zung Thai, MD
415-225-9338
zung@edgewoodonc.com
Edgar Bautista, BS
edgar@edgewoodonc.com
Alexander Philipovskiy, MD, PhD
Florida Cancer Specialists
Interventions
  • Drug: BTX-A51 — One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
Study Locations (6 sites)
Florida Cancer Specialists, Lake Mary, Florida 32746 United States
Florida Cancer Specialists, Sarasota, Florida 34232 United States
The Linder Research Center at The Christ Hospital, Cincinnati, Ohio 45219 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
Tennessee Oncology, PLLC, Nashville, Tennessee 37203 United States
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Demonstration of understanding and voluntarily signing of an informed consent form * Age ≥ 18 years * Histologically or cytologically documented, incurable or metastatic solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available * Phase 1b and 1c only: Histologically confirmed diagnosis of ER+, HER2- mBC not amenable to resection or radiation therapy with curative intent. * Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). * Adequate organ function * Females of childbearing age must not be pregnant at time of Screening/beginning of treatment and agree to either abstain from sexual intercourse or use highly effective methods of contraception (for up to 3 months after last dose of study drug) * Males sexually active with a woman of childbearing age must agree to use barrier method of birth control during and after the study (up to 3 months after last dose of study drug) Exclusion Criteria: * Life expectancy \<3 months, as determined by the Investigator. * Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of BTX-A51 * Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to first dose of BTX-A51 * Major trauma or major surgery within 4 weeks prior to first dose of BTX-A51. * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 except for alopecia or Grade ≤2 immunotherapy-related thyroid toxicity. * History of, or known, central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. * Clinically significant cardiac disease * Active uncontrolled systemic fungal, bacterial, mycobacterial, or viral infection * Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) * Active hepatitis C virus (HCV) or hepatitis B virus (HBV) * Second primary malignancy that has not been in remission for greater than 3 years * Any serious underlying medical (e.g., pulmonary, renal, hepatic, gastrointestinal, or neurological) or psychiatric condition (e.g., alcohol or drug abuse, dementia or altered mental status) or any issue that would limit compliance with study requirements * Pregnant, lactating, or breastfeeding. * Participation or plans to participate in another interventional clinical study.
Conditions Type 2 Diabetes
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To investigate the effect of nitrate supplementation on red blood cell function in patients with type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Beet root juice — 70 ml bid
  • Dietary Supplement: Placebo juice — 70 ml bid

Primary Outcomes

  • Percentage recovery of left ventricular function (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • John Pernow (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet
Contact Information
Study Contact:
John Pernow
+46704848361
john.pernow@ki.se
John Pernow, Dr
+46851775876
john.pernow@ki.se
Karolinska Institutet, Karolinska University Hospital
Interventions
  • Dietary Supplement: Beet root juice — 70 ml bid
  • Dietary Supplement: Placebo juice — 70 ml bid
Study Locations (1 sites)
Karolinska Institutet, Karolinska University Hospital, Stockholm, 17176 Sweden
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes Exclusion Criteria: Acute coronary syndrome Vegetarian diet Impaired renal function Absolute indication for proton pump inhibitor Ongoing treatment with organic nitrate Heart failure (ejection fraction \<35%) Any condition that interferes with the possibility to fulfill the study protocol
Conditions Gut Microbiota, Gastrointestinal Symptom...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This mother-infant cohort study aims to determine the geographic differences in the microbial profiles in breast milk from mothers living in Malaysia and China that are potentially important determinants of infant development. It also aims to determine the impact of gut microbiome on infant health (temperament, gastrointestinal symptoms, eczema symptoms, and asthma symptoms).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention - mother-infant cohort study — There are no interventions because it is a mother-infant cohort study

Primary Outcomes

  • Breastmilk microbiome (from birth to 12 months)
  • Gut microbiome (from birth to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-06-03
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiti Putra Malaysia
Collaborators: Guilin University of Technology, China, National Engineering Center of Dairy for Maternal and Child Health, Beijing
Principal Investigators:
  • Wan Ying Gan, PhD (PRINCIPAL_INVESTIGATOR) - Universiti Putra Malaysia
  • Tie Min Jiang (PRINCIPAL_INVESTIGATOR) - Guilin University of Technology
  • Li Jun Chen, PhD (STUDY_DIRECTOR) - Beijing Sanyuan Foods Co Ltd
Contact Information
Study Contact:
Shiang Yen Eow, PhD student
017-6803715
cescvin423@hotmail.com
Wan Ying Gan, PhD
012-3564352
wanying@upm.edu.my
Private hospital
Private hospital
Interventions
  • Other: No intervention - mother-infant cohort study — There are no interventions because it is a mother-infant cohort study
Study Locations (1 sites)
Private hospital, Kajang, Selangor 43000 Malaysia
Eligibility Criteria
Inclusion Criteria: * Pregnant women aged between 18 and 45 years old * Pregnant women who attend the antenatal check-up at the selected clinics/hospitals * Pregnant women with the gestational age of less than 12 weeks * Pregnant women who plan to attend post-natal check-ups for at least one year at the same clinic/hospital Exclusion Criteria: * Pregnant women who are diagnosed with immune deficiency * Pregnant women who have a multiple pregnancy and preterm delivery (\<37 weeks) * Pregnant women who plan to move out of the study area in the next one year * Pregnant women with fetal/newborn with congenital abnormalities
Conditions Breast Cancer
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: Harmonic motion imaging — Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.

Primary Outcomes

  • Assessment of the correlation between change in HMI measurements and pathologic response at completion of neoadjuvant therapy (Baseline and through neoadjuvant therapy completion (an average of 28 weeks))
  • Assessment of the correlation between change in HMI measurements and pathologic response during neoadjuvant systemic therapy (Baseline and during short-interval on treatment (approximately 4 weeks after treatment initiation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-14
Completion: 2026-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Elisa Konofagou, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Elisa Konofagou, PhD
212-342-1612
ek2191@columbia.edu
Yangpei Liu, MSc
212-342-1612
yl4786@columbia.edu
Elisa Konofagou, PhD
212-342-1612
ek2191@columbia.edu
Columbia University Irving Medical Center/NYP
Interventions
  • Procedure: Harmonic motion imaging — Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
Study Locations (1 sites)
Columbia University Irving Medical Center/NYP, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Women age ≥18 * Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician. * Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm Exclusion criteria: * Patient is pregnant or lactating * Presence of breast implants * History of laser or radiation therapy to the affected breast
Conditions Depression, Addiction, Domestic Violence...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

COVID-19 has placed unprecedented strains on parents impacted by toxic stressors (depression, addiction, family violence, and poverty) and reluctant to see mental health-service providers in home/clinic due to fears of infection. Due to the pandemic, PI Letourneau ceased/delayed recruitment in ATTACH™, a CIHR-funded randomized controlled trials (RCT) of in-person (home or clinic) program designed to improve children's mental, emotional and behavioral (MEB) health and development via parent-child relationship intervention. Recognizing the heightened need for already vulnerable families to obtain safe parenting support to manage depressive symptoms/other stressors. The team's primary knowledge user (D. McNeil, Scientific Director, Maternal Newborn Child and Youth Strategic Clinical Network, Alberta Health Services) advocated for online delivery of the ATTACH™ parent training program. In response, an interdisciplinary team from nursing and software engineering rapidly pivoted to an online delivery format. Critical barriers to using existing commercial technologies emerged, making it essential to develop and implement tailored, user-informed virtual care delivery platforms and tools safe, secure, user-friendly for families already stressed. Innovative user interface design and integrated knowledge transfer approaches will be used to: (a) adapt ATTACH™ for virtual delivery; (b) develop virtual platforms (web-based applications) and tools (mobile apps) for flexible delivery of mental health supports for parents and training for professional facilitators; (c) integrate virtual mental health services into the primary care system promoting program uptake; and (d) design/test streamlined and intuitive virtual systems for nimble spread/scaleup. The project catalyzes and enriches the PIs' research program by crossing disciplines (nursing \& engineering) in cutting edge research that is responsive to trends in both mental health intervention and web-interface design. The aim is to adapt, develop, design and pilot test virtual (web-based) intervention program to improve children's mental, emotional and behavioral (MEB) health and development. This will be done by building on successful CIHR funded in-person (home or clinic) programs and pivoting to user-engaged program development, adaptation and pilot testing for virtual delivery in the face of COVID19.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Attachment and Child Health (ATTACH) Parenting Program — ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.

Primary Outcomes

  • Mother Child interaction Quality will be assessed by Parent Child Interaction Teaching Scale (PCITS) (Change from baseline PCITS scores after completion of intervention (an average of 10 weeks).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-03-15
Completion: 2027-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Calgary
Contact Information
Study Contact:
Nicole Letourneau, RN, PhD
403-210-3833
nicole.letourneau@ucalgary.ca
University of Calgary
Interventions
  • Behavioral: Attachment and Child Health (ATTACH) Parenting Program — ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
Study Locations (1 sites)
University of Calgary, Calgary, Alberta T2N 1N4 Canada
Eligibility Criteria
Inclusion Criteria: * parents with children between birth and 32 months of age (based on selection of age-appropriate tools for assessing children's health and development) * parents agree to participate in the ATTACH™ program consisting of 10-12 weeks of one-hour per week parent training sessions * parents agreed to bring a co-parent for 2-3 of the 10 sessions (when possible) * parents agree to the dried blood sample collection from themselves and their children (in Calgary agencies) Exclusion Criteria: \-
Conditions Breast Cancer, Breast Neoplasms, Anatomi...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a priority in clinical research due to its dramatic impact on daily functioning, quality of life, and long-term health. Aerobic exercise has the potential to improve cognitive function and brain health in older adults and is recommended as a safe, tolerable, and accessible complementary therapy for breast cancer survivors. This study aims to understand the effects of physical activity compared with health education on memory, attention, and brain health in women with breast cancer. Study findings may help researchers design more programs that can improve memory, attention, and brain health in other women with breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Aerobic Exercise Training — Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
  • Other: Health Education (Active comparator) — Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.

Primary Outcomes

  • Change in inhibitory control (baseline (Month 0), post-intervention (month 6), follow up (month 12))
  • Change in cognitive flexibility (baseline (Month 0), post-intervention (month 6), follow up (month 12))
  • Change in executive function processing (baseline (Month 0), post-intervention (month 6), follow up (month 12))
  • Change in short-term memory (baseline (Month 0), post-intervention (month 6), follow up (month 12))
  • Change in verbal memory (baseline (Month 0), post-intervention (month 6), follow up (month 12))
  • Change in working memory (baseline (Month 0), post-intervention (month 6), follow up (month 12))
  • Change in brain volume (baseline (Month 0), post-intervention (month 6))
  • Change in white matter integrity (baseline (Month 0), post-intervention (month 6))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-22
Completion: 2027-07-31
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Diane K. Ehlers, Ph.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Melissa Cole, MS
480-574-4052
cole.melissa@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Melissa Cole, MS
480-574-4052
cole.melissa@mayo.edu
Mayo Clinic in Arizona
Interventions
  • Behavioral: Aerobic Exercise Training — Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
  • Other: Health Education (Active comparator) — Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
Study Locations (1 sites)
Mayo Clinic in Arizona, Phoenix, Arizona 85054 United States
Eligibility Criteria
Inclusion Criteria * PRE-REGISTRATION: Age ≥50 years at time of pre-registration visit according to participant report and/or clinical determination * PRE-REGISTRATION: First, primary diagnosis of stage I-IIIa breast cancer according to participant report and/or clinical determination * PRE-REGISTRATION: Post-surgery and completed primary treatment (i.e., surgery, chemotherapy, and/or radiation therapy) 3-60 months prior to registration according to participant report and/or clinical determination * PRE-REGISTRATION: Sedentary except for casual lifestyle recreation defined as self-reporting no more than 90 minutes per week of moderate-intensity aerobic exercise within the last 6 months * PRE-REGISTRATION: Self-reported ability to complete assessments by themselves or with assistance * REGISTRATION: Age ≥50 years as confirmed via clinical determination * REGISTRATION: Able to provide medical record release to confirm eligibility * REGISTRATION: First, primary diagnosis of stage I-IIIa breast cancer as confirmed via clinical determination * REGISTRATION: Post-surgery and completed primary treatment (i.e., surgery, chemotherapy, and/or radiation therapy) 3-60 months prior to pre-registration as confirmed via clinical determination * REGISTRATION: No evidence of possible cognitive impairment as assessed using the Telephone Interview of Cognitive status (13-item modified version) (TICS-M; score \> 21) NOTE: Only individuals who pass the TICS-M during pre-registration will be invited to participate in the urine substudy * REGISTRATION: Receive physician's clearance to participate in an exercise program NOTE: Individuals with conditions/diagnoses deemed important by the primary investigator will be required to provide clearance for exercise from their cardiologist. Example conditions include: * History of major multiple myocardial infarctions (MI) * Recent electrocardiogram (ECG) changes or recent MI * Resting or unstable angina * Significant multivessel coronary occlusion (≥ 70%) on angiography * Uncontrolled and/or serious arrhythmias * 3rd degree heart block * Acute congestive heart failure or ejection fraction \< 30% * REGISTRATION: Ability to complete assessments by themselves or with assistance Exclusion Criteria: * PRE-REGISTRATION: Stage 0 breast cancer diagnosis OR metastatic disease * PRE-REGISTRATION: Currently receiving or \< 3 months since receiving chemotherapy or radiation therapy for cancer, or greater than 60 months post primary treatment * PRE-REGISTRATION: Planned surgery during the intervention period * PRE-REGISTRATION: Second cancer diagnosis (excluding non-invasive skin cancers or carcinoma-in-situ for any cancer) * PRE-REGISTRATION: Unable to travel regularly to the study locations for intervention sessions and data collection * PRE-REGISTRATION: Unwilling to return to enrolling institution for follow-up * PRE-REGISTRATION: Self-reported inability to walk without assistance or devices * REGISTRATION: History of stroke, transient ischemic attack, other neurological disorders, or brain surgery involving tissue removal as confirmed via clinical determination * REGISTRATION: Clinically significant TICS-M score (\< 21) during baseline procedures * REGISTRATION: Not able to provide physician re-clearance for exercise if required based upon clinically significant baseline exercise test (as determined by ECG and blood pressure monitoring) * REGISTRATION: Contraindications to functional magnetic resonance imaging (fMRI) in accordance with the Mayo Clinic Department of Radiology safety protocols * REGISTRATION: Clinically significant MRI scan as determined by physician review in which the following is advised via radiologist overread: remarkable/abnormal limited diagnostic brain image with recommended medical follow-up * REGISTRATION: Enrolled in another physical activity program * REGISTRATION: Unable to walk without assistance or devices * REGISTRATION: Unwilling to complete study requirements * REGISTRATION: Unwilling to be randomized to the exercise group or health education group * REGISTRATION: Unable or unwilling to continuously wear and regularly sync/charge an activity tracker during the study period * REGISTRATION: Unable to travel regularly to the study locations for intervention sessions and data collection * REGISTRATION: Unwilling to return to enrolling institution for follow-up
Conditions Rhinitis, Allergic, Rhinoconjunctivitis,...
Phase PHASE3
Enrollment 180
Locations 27 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: 10,000 MG01 +10,000 T521 — Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
  • Biological: 30,000 MG01 +10,000 T521 — Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
  • Other: Placebo subcutaneous — The same solution and presentation as the active treatment, but without active ingredients

Primary Outcomes

  • RCSMS: Combined Symptoms and Medication Score of rhinitis. Combined symptom and medication score in rhinitis/rhinoconjunctivitis (RCSMS) (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-05-31
Completion: 2026-10
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inmunotek S.L.
Principal Investigators:
  • Pedro Ojeda, MD (STUDY_DIRECTOR) - Clínica privada Dres Ojeda
Contact Information
Study Contact:
Miguel Casanovas, MD PhD
+34 912908942
mcasanovas@inmunotek.com
Raquel Caballero
+34 607600638
rcaballero@inmunotek.com
Alicia Alonso, MD
+34 983358000
aliciaalonsogomez@gmail.com
Hospital Recoletas Felipe Ii
Interventions
  • Biological: 10,000 MG01 +10,000 T521 — Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
  • Biological: 30,000 MG01 +10,000 T521 — Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
  • Other: Placebo subcutaneous — The same solution and presentation as the active treatment, but without active ingredients
Study Locations (27 sites)
Hospital Recoletas Felipe Ii, Valladolid, Castille and León 47003 Spain
Cedt de Tarancón, Tarancón, Cuenca 16400 Spain
Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid 28806 Spain
Hospital U. Fundación Alcorcón, Alcorcón, Madrid 28922 Spain
Hospital Cruz Roja Madrid, Madrid, Madrid 28003 Spain
Clínica Privada Dres Ojeda, Madrid, Madrid 28006 Spain
Hospital Universitario Puerta de Hierro, Majadahonda, Madrid 28222 Spain
Clínica Privada Murcia, Murcia, Murcia 30006 Spain
Hospital Nuestra Señora de Sonsoles, Ávila, 05071 Spain
Fundación Hospital Sant Pere Claver, Barcelona, 08004 Spain
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent. 2. Aged between 12 and 65, both genders 3. Positive suggestive clinical history of intermittent or persistent moderate to severe rhinitis /rhinoconjunctivitis according to ARIA classification, with or without moderate intermittent or persistent asthma,according to GEMA 5.0, due to grass and cupressaceae pollen. 4. Subjects with a positive skin prick-test (wheal size \>5 mm diameter) to a standardized mixed extract of grass pollen (Phleum pratense, Holcus lanatus, Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne) or to one of the molecular components of the mixture and to a cupressaceae extract. In addition, the largest diameter of the papules must be greater than or equal to that of the histamine. 5. Specific IgE \> 3,5 KU/L , against grass (preferably Phleum pratense) and cupressaceae pollen (InmunoCAP® o Immulite). 6. Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial. 7. Women of childbearing potential participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives. 8. Subjects capable of complying with the dosing regimen. 9. Subjects who own a smartphone for symptom registration and medication. 10. Subjects with a negative prick test to coestational pollens. In the case specific IgE is available, the result should be \<3,5 kU/L and without relevant symptomatology 11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliums and fungus). In the case specific IgE is available, the result should be \<3,5 kU/L and without relevant symptomatology. Exclusion Criteria: 1. Subjects with positive prick test to other aeroallergens except for sensitisation to epithelia with occasional exposure and symptoms. 2. Subjects with positive prick test to other aeroallergens except for sensitisation to pollen noncoseasonal with cupressus or grasses. 3. Subjects who have received prior immunotherapy in the preceding 5 years for any of the allergens tested or a cross-reactive allergen or are currently receiving immunotherapy with any allergen. 4. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee. 5. Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1 \<70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis / rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated. 6. Subjects who have previously had a severe secondary reaction during the prick test diagnostic skin test. 7. Subjects treated with beta-blockers. 8. Clinically unstable subjects at the time of inclusion in the trial (acute asthmatic exacerbation, respiratory infection, febrile process, acute urticaria, etc.). 9. Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema. 10. Subjects who have any pathology in which adrenaline administration is contraindicated (hyperthyroidism, HTN, heart disease, etc.). 11. Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but potentially serious and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multioperated patients, kidney disease,). 12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies. 13. Subject whose condition prevents from offering cooperation and/ or who has severe psychiatric disorders. 14. Subjects with a known allergy to components of the investigational medicinal product other than the allergen. 15. Subjects with lower respiratory diseases other than asthma such as emphysema or bronchiectasis. 16. Subjects who are direct relatives of the researchers. 17. Pregnant or lactating women.

Transdiagnostic Cognitive Biomarkers

NCT04864080
Recruiting
Conditions Pain, Depression
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall objective of this study is to determine the feasibility of identifying transdiagnostic biomarkers of cognitive function mediated by neuromodulation of the dorsolateral prefrontal cortex that are translatable across disease groups in order to more accurately phenotype clusters of cognitive dysfunction. Completing behavioral paradigms with electrophysiology and TMS is a challenging frontier. This study focuses on the feasibility of such an endeavor for those with chronic pain or depression as well as healthy controls.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Behavioral: Computer game/task — N-back, COGED, PacMan game, Bandit task, Websurf task.
  • Behavioral: Health surveys online — Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.

Primary Outcomes

  • Feasibility for all aspects of the study (1-7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-11
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Contact Information
Study Contact:
David Darrow
(612) 624-6666
hdlab@umn.edu
MATTHEW D Maple
612-946-1424
maple036@umn.edu
David Darrow
612-946-1424
hdlab@umn.edu
University of Minnesota
Interventions
  • Behavioral: Computer game/task — N-back, COGED, PacMan game, Bandit task, Websurf task.
  • Behavioral: Health surveys online — Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Arm 1, healthy controls: Inclusion Criteria: * Have access to the online study platform. Exclusion Criteria: * under 18, non-English speaking Arm 2: pain and depression: Inclusion Criteria: * Pain or depression Exclusion Criteria: * pregnant women
Conditions Cervical Cancer, Gastric/Gastroesophagea...
Phase PHASE1, PHASE2
Enrollment 1109
Locations 47 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BMS-986340 — Specified dose on specified days
  • Drug: BMS-936558-01 — Specified dose on specified days
  • Drug: Docetaxel — Specified dose on specified days
  • Drug: Pumitamig — Specified dose on specified days

Primary Outcomes

  • Incidence of adverse events (AEs) (Up to 120 weeks)
  • Incidence of serious adverse events (SAEs) (Up to 120 weeks)
  • Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria (Up to either 21 or 28 days)
  • Incidence of AEs leading to discontinuation (Up to 120 weeks)
  • Number of deaths (Up to 120 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-05-27
Completion: 2031-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1109 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bristol-Myers Squibb
Principal Investigators:
  • Bristol-Myers Squibb (STUDY_DIRECTOR) - Bristol-Myers Squibb
Contact Information
Study Contact:
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Uzair Chaudhary, Site 0032
559-387-1600
Community Cancer Institute
Interventions
  • Drug: BMS-986340 — Specified dose on specified days
  • Drug: BMS-936558-01 — Specified dose on specified days
  • Drug: Docetaxel — Specified dose on specified days
  • Drug: Pumitamig — Specified dose on specified days
Study Locations (47 sites)
Community Cancer Institute, Clovis, California 93611 United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California 92663 United States
University of Iowa, Iowa City, Iowa 52242 United States
John Theurer Cancer Center, Hackensack, New Jersey 07601 United States
Local Institution - 0006, New York, New York 10032 United States
Local Institution - 0002, New York, New York 10065 United States
Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon 97213 United States
Local Institution - 0063, Nashville, Tennessee 37204 United States
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria * Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable. * Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Radiographically documented progressive disease on or after the most recent therapy. * Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated. * Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant. Exclusion Criteria * Women who are pregnant or breastfeeding. * Primary central nervous system (CNS) malignancy. * Untreated CNS metastases. * Leptomeningeal metastases. * Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment. * Active, known, or suspected autoimmune disease. * Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment. * Prior organ or tissue allograft. * Uncontrolled or significant cardiovascular disease. * Major surgery within 4 weeks of study drug administration. * History of or with active interstitial lung disease or pulmonary fibrosis. * Other protocol-defined inclusion/exclusion criteria apply.
Conditions Postpartum Depression, Preterm Labor
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) or 8 weeks of 2000 IU vitamin D supplementation will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Behavioral: Mindfulness-based intervention (with a focus on self-compassion; MBSC) — 8-week MBSC intervention with a focus on increasing self-compassion
  • Dietary Supplement: Vitamin D — Vitamin D at 2,000 IU/day for 8 weeks.

Primary Outcomes

  • Maternal Stress - Biomarker Change (Baseline to 4 and 8 weeks)
  • Maternal Stress - Psychometric Measure Change (Baseline to 4 and 8 weeks)
  • Maternal Self-compassion - Biomarker Change (Baseline to 4 and 8 weeks)
  • Maternal Self-compassion - Psychometric Measure Change (Baseline to 4 and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-05-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Idaho
Collaborators: Oregon State University, National Institute of General Medical Sciences (NIGMS), Kootenai Health
Principal Investigators:
  • Yimin Chen, PhD (PRINCIPAL_INVESTIGATOR) - University of Idaho
Contact Information
Study Contact:
Yimin Chen, PhD
2088857264
yiminc@uidaho.edu
Brook Lang, MD
Kootenai Health
Interventions
  • Behavioral: Mindfulness-based intervention (with a focus on self-compassion; MBSC) — 8-week MBSC intervention with a focus on increasing self-compassion
  • Dietary Supplement: Vitamin D — Vitamin D at 2,000 IU/day for 8 weeks.
Study Locations (1 sites)
Kootenai Health, Coeur d'Alene, Idaho 83814 United States
Eligibility Criteria
Inclusion Criteria: * Mothers of newborn infants at Kootenai Health NICU and the Palouse region Exclusion Criteria: \-